The Vivitrol pilot program (VPP): initial quantitative findings from an extended-release naltrexone study
نویسندگان
چکیده
Background In 2010, the FDA approved the use of extended-release injectable naltrexone (Vivitrol©) for the treatment of opioid dependence. Preliminary evidence from prior studies indicates that monthly injections of Vivitrol are effective in treating opioid dependence after initial detoxification. This longitudinal exploratory study measures demographics, medication adherence, sobriety (urinalysis), utilization of care, and mental and emotional states in patients who were treated for opioid dependence with injectable naltrexone at an addictions stabilization center.
منابع مشابه
Naltrexone long-acting formulation in the treatment of alcohol dependence
While oral naltrexone has a demonstrated ability to decrease alcohol reinforcement, it also has pharmacotherapeutic limitations, such as a small treatment effect size, adverse events, and plasma level fluctuations. The pharmacokinetic profile of naltrexone could be enhanced by intramuscular administration, which would sustain its release over several weeks and keep plasma levels relatively cons...
متن کاملWhose mu fared better? The effect of extended-release naltrexone (XR-NTX) on treatment outcomes for opioid and alcohol users
Background In 2010, Los Angeles County made the decision to offer publicly funded patients receiving treatment for substance use disorders extended-release naltrexone (XR-NTX, brand name “Vivitrol”). Since 2010, over 1200 patients have received at least one dose of extended-release naltrexone. Little is known concerning the differential impact of the medication on those who use it for alcohol u...
متن کاملPharmacological enhancement of naltrexone treatment for opioid dependence: a review
PURPOSE: Opioid dependence (OD) is a serious and growing clinical condition with increasing social costs that requires expanding treatment beyond opioid agonist substitution. The opioid antagonist naltrexone has displayed a remarkable association of theoretical effectiveness and poor clinical utility in treating OD due to noncompliant behavior and low acceptability among patients, only partly m...
متن کاملThe relative bioavailability of morphine sulfate and naltrexone hydrochloride extended release capsules (EMBEDA®) and an extended release morphine sulfate capsule formulation (KADIAN®) in healthy adults under fasting conditions.
Morphine sulfate and naltrexone hydrochloride extended release capsules (EMBEDA®, King Pharmaceuticals®, Inc., Bristol, TN), indicated for the management of chronic, moderate to severe pain, contain extended release morphine pellets with a sequestered naltrexone core (MS-sNT). If the product is tampered with by crushing, naltrexone, a μ-opioid antagonist, is intended for release to mitigate mor...
متن کاملMorphine sulfate and naltrexone hydrochloride extended-release capsules: naltrexone release, pharmacodynamics, and tolerability.
BACKGROUND Morphine sulfate and naltrexone hydrochloride extended-release capsules (EMBEDA, King Pharmaceuticals, Inc., Bristol, TN), indicated for management of chronic, moderate-to-severe pain, contain pellets of extended-release morphine sulfate with a sequestered naltrexone core (MS-sNT). Taken as directed, morphine provides analgesia while naltrexone remains sequestered; if tampered with b...
متن کامل